PCM
ADAP

Prelude Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Prelude Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-25,181
Closed -$23.3K – 1112
2023
Q2 		$23.3K Buy
+25,181
New +$30K ﹤0.01% 1008
2019
Q3 		– Sell
-2,204
Closed -$9K – 1668
2019
Q2 		$9K Buy
2,204
+1,385
+169% +$5.65K ﹤0.01% 1413
2019
Q1 		$4K Sell
819
-98
-11% -$456 ﹤0.01% 1646
2018
Q4 		$5K Sell
917
-51,842
-98% -$383K ﹤0.01% 1605
2018
Q3 		$715K Sell
52,759
-139
-0.3% -$1.46K 0.04% 439
2018
Q2 		$628K Sell
52,898
-46,796
-47% -$583K 0.04% 466
2018
Q1 		$1.12M Buy
99,694
+40,841
+69% +$357K 0.08% 251
2017
Q4 		$393K Buy
58,853
+14,294
+32% +$110K 0.03% 476
2017
Q3 		$365K Sell
44,559
-53,624
-55% -$335K 0.03% 456
2017
Q2 		$441K Buy
98,183
+78,677
+403% +$411K 0.04% 354
2017
Q1 		$107K Buy
+19,506
New +$85.3K 0.01% 764
2016
Q2 		– Sell
-24,900
Closed -$202K – 1551
2016
Q1 		$202K Buy
+24,900
New +$204K 0.03% 549

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Prelude Capital Management's ADAP Position: Q3 2023 in Review

Prelude Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2023, closing a stake of 25,181 shares — an estimated $23.3K sold.

Prelude Capital Management first reported a position in ADAP in Q1 2016 and held it in 12 quarters. The position peaked at $1.12M in Q1 2018. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2023.

  • Prelude Capital Management reported no remaining Adaptimmune Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Prelude Capital Management sold 25,181 Adaptimmune Therapeutics shares in Q3 2023, an estimated $23.3K.
  • Prelude Capital Management first reported a position in Adaptimmune Therapeutics in Q1 2016 and held it in 12 quarters.
  • Prelude Capital Management's Adaptimmune Therapeutics position peaked at $1.12M in Q1 2018.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.